You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed cell death protein-1 inhibitor

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

Recruiting
  • Breast Cancer
  • +2 more
  • Observational Study
  • Lucknow, Uttar Pradesh, India
    Sanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022

Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

Active, not recruiting
  • Metastatic Nonsmall Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Stereotactic Body Radiotherapy
  • Philadelphia, Pennsylvania
    Philadelphia CyberKnife
Mar 15, 2022

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)

Not yet recruiting
  • Locally Advanced Basal Cell Carcinoma
  • Cemiplimab
  • +3 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University Hospital
Jun 28, 2023

Safety of ICIs and TKIs Therapy for HCC

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Lenvatinib Oral Product
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
Has Results
  • Neoplasms
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

Withdrawn
  • Malignant Melanoma
  • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
  • (no location specified)
Nov 12, 2021

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Hepatocellular Carcinoma Trial in Shanghai (Toripalimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital
Jun 14, 2021

Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

Recruiting
  • Large B-cell Lymphoma
  • 89Zr-atezolizumab PET-imaging
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 15, 2022

Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital
Jul 23, 2021

The Gut Microbiome and Immunotherapy Response in Solid Cancers

Recruiting
  • Cancer
    • Galveston, Texas
      University of Texas Medical Branch
    Sep 15, 2023

    EBV Infection Trial in Suzhou (PD-1 mAb)

    Recruiting
    • EBV Infection
    • PD-1 monoclonal antibody
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Sep 1, 2021

    Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

    Recruiting
    • Urothelial Carcinoma
    • Zilovertamab vedotin
    • Cleveland, Ohio
    • +11 more
    Jan 25, 2023

    Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

    Completed
    • Neoplasm
    • Chuo-Ku, Japan
    • +1 more
    Nov 3, 2022

    Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Endometrial Serous Adenocarcinoma
    • Biospecimen Collection
    • +4 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    May 12, 2023